Inhibition of PAK1 suppresses pancreatic cancer by stimulation of anti-tumour immunity through down-regulation of PD-L1-Reference-Cited by-同舟云学术

Inhibition of PAK1 suppresses pancreatic cancer by stimulation of anti-tumour immunity through down-regulation of PD-L1

Published:2020-03 Issue: Volume:472 Page:8-18
ISSN:0304-3835
Container-title:Cancer Letters
language:en
Short-container-title:Cancer Letters

Author:

Wang Kai,Zhan Yifan,Huynh Nhi,Dumesny Chelsea,Wang Xiao,Asadi Khashayer,Herrmann David,Timpson Paul,Yang Yang,Walsh Katrina,Baldwin Graham S.,Nikfarjam Mehrdad,He Hong

Funder

Austin Medical Research Foundation

Tour de Cure Charity

Pancare Foundation

Melbourne International Fee Remission Scholarship

Melbourne International Research Scholarship

Moshe Sambor Scholarship

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference54 articles.

1. Cancer statistics;Siegel;Ca - Cancer J. Clin.,2019

2. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes;Agata;Int. Immunol.,1996

3. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer;Nomi;Clin. Cancer Res.,2007

4. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer;Brahmer;N. Engl. J. Med.,2012

5. Phase I study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in patients with advanced solid tumors;Patnaik;Clin. Cancer Res.,2015

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PAK1 inhibition increases TRIM21-induced PD-L1 degradation and enhances responses to anti-PD-1 therapy in pancreatic cancer;Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease;2024-08

2. Targeting PAK1 is effective against cutaneous squamous cell carcinoma in a syngenic mouse model;Cancer Science;2024-06-19

3. Inhibition of P21-activated kinases 1 and 4 synergistically suppresses the growth of pancreatic cancer by stimulating anti-tumour immunity;Cell Communication and Signaling;2024-05-27

4. Rapamycin vs TORin-1 or Gleevec vs Nilotinib: Simple chemical evolution that converts PAK1-blockers to TOR-blockers or vice versa?;Drug Discoveries & Therapeutics;2024-04-30

5. Inhibition of P21-activated kinases 1 and 4 synergistically suppress the growth of pancreatic cancer by stimulating anti-tumour immunity;2024-03-11